Co-Diovan 160 mg/12,5 mg filmom obložene tablete
| Name | Co-Diovan 160 mg/12,5 mg filmom obložene tablete |
|---|---|
| Marketing Authorisation Number | HR-H-819796318 |
| Active Substance | valsartan hidroklorotiazid |
| Composition | svaka filmom obložena tableta sadrži 160 mg valsartana i 12,5 mg hidroklorotiazida |
| Pharmaceutical Form | filmom obložena tableta |
| Manufacturer | Novartis Pharma GmbH, Nürnberg, Njemačka Novartis Farma S.p.A., Torre Annunziata (Napulj), Italija Novartis Farmacéutica S.A., Barcelona, Španjolska |
| Marketing Authorisation Holder | Novartis Hrvatska d.o.o., Radnička cesta 37b, Zagreb, Hrvatska |
| Marketing Authorisation Date | 09.02.2016 |
| MA Period of Validity | unlimited |
| Classification Number | UP/I-530-09/15-02/311 |
| Registration Number | 381-12-01/30-16-06 |
| Prescription | Medicinal product subject to medical prescription |
| Type of prescription | ponovljivi recept |
| Distribution | Supply through pharmacies (community) |
| Advertising to general public | not allowed |
| ATC Code | C09DA03 |
| Marketing status | stavljeno u promet |
| Shortage status | nema nestašice |
| SmPC | download |
| PL | download |
| Public Assessment Report | download |
Packaging
Direct Healthcare Professional Communication
| Name | Date | Download |
|---|---|---|
| Pismo zdravstvenim radnicima o riziku od nemelanomskog raka kože povezanog s primjenom hidroklorotiazida | 17.10.2018 | Alkaloid, Belupo, Berlin-Chemie Menarini, Boehringer Ingelheim International, Farmal, Genericon, Pharma, Jadran Galenski laboratorij, Krka - farma, Merck, Merck Sharp & Dohme, Novartis, PharmaSwiss, Pliva, Sandoz, sanofi-aventis i Stada |
